| アブストラクト | AIMS: This study aimed to describe baseline characteristics and adherence among patients with transthyretin amyloid cardiomyopathy (ATTR-CM) treated with tafamidis (VYNDAQEL(R)) in Japan using the Japanese Medical Data Vision (MDV) database. METHODS AND RESULTS: This study was a non-interventional, retrospective cohort study of adult (>/=18 years old) patients in the Japanese MDV claims database diagnosed with ATTR-CM and with at least two tafamidis prescriptions of dose strength 4 x 20 mg/day between 1 March 2019 and 31 August 2021. The date of the first prescription was defined as the index date, with follow-up time defined as the time between the first and last prescription plus the days' supply from the last refill. Baseline characteristics were assessed during a 12 month pre-index period. Adherence was measured using two metrics: (i) the modified medication possession ratio (mMPR), calculated by taking the sum of days supplied for all fills within the follow-up period, divided by the number of days of follow-up, and reported as a percentage, with patients classified as adherent with an mMPR of >/=80%, and (ii) the proportion of days covered (PDC), calculated by taking the total number of days' supply dispensed during the follow-up period divided by the number of days of follow-up, adjusting for any days' supply overlap. A total of 210 patients were identified; the mean (standard deviation) age of the cohort was 77 (5.9) years, and the majority (89%) were male. The most common baseline cardiovascular comorbidities were heart failure (85%), ischaemic heart disease (66%), hypertensive diseases (49%), and diabetes (35%); 75% of patients received heart failure medications in the 12 months prior to index, with the most common being beta-blockers (49%), diuretics (48%), angiotensin receptor blockers (30%), angiotensin-converting enzyme inhibitors (22%), and sodium-glucose cotransporter-2 inhibitors (8.1%). Over an average 14 month follow-up, mean mMPR was 96% with a median of 100% [inter-quartile range (IQR): 97-101%]; 93% of patients were adherent (defined as an mMPR >/= 80%). In the same follow-up period, mean PDC was 93.6% with a median of 99% (IQR: 93-100%). Persistence was high with 78% of patients having a 0 day gap between prescription refills. CONCLUSIONS: This study found high adherence rates to tafamidis in this real-world Japanese patient population. Adherence rates in this study were similar to those reported by the tafamidis clinical trial and a previously published US commercial claims adherence analysis. Further studies should be conducted to assess the impact of real-world adherence on real-world outcomes. |
|---|
| ジャーナル名 | ESC heart failure |
|---|
| Pubmed追加日 | 2024/5/24 |
|---|
| 投稿者 | Kato, Takao; Ines, Monica; Minamisawa, Masatoshi; Benjumea, Darrin; Keohane, Denis; Alvir, Jose; Kim, Ruth; Chen, Yong; Peixoto, Telma; Kent, Matthew; Wogen, Jenifer; Ishii, Tomonori; Crowley, Aaron; Sugino, Toshiya; Izumiya, Yasuhiro |
|---|
| 組織名 | Department of Cardiovascular Medicine, Institute for Advancement of Clinical and;Translational Science, Kyoto University Hospital, Kyoto, Japan.;Pfizer Portugal, Porto Salvo, Portugal.;Department of Cardiovascular Medicine, Shinshu University School of Medicine,;Matsumoto, Japan.;Genesis Research Group, Hoboken, NJ, USA.;Pfizer Inc., New York, NY, USA.;Pfizer Inc., Collegeville, PA, USA.;Pfizer Japan Inc., Tokyo, Japan.;Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate;School of Medicine, Osaka, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38783561/ |
|---|
